Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 3 |
2023 | 3 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer.
Genes Cancer. 2023 Mar 10;14:30-49. doi: 10.18632/genesandcancer.231. eCollection 2023.
Genes Cancer. 2023.
PMID: 36923647
Free PMC article.
Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin.
Chang WH, Liu Y, Hammes EA, Bryant KL, Cerione RA, Antonyak MA.
Chang WH, et al.
J Biol Chem. 2023 Feb;299(2):102842. doi: 10.1016/j.jbc.2022.102842. Epub 2022 Dec 26.
J Biol Chem. 2023.
PMID: 36581205
Free PMC article.
Item in Clipboard
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, Beelen AP, Bublitz N, Lüthen M, Wood KC, Petricoin EF, Sers C, McRee AJ, Cox AD, Der CJ.
Goodwin CM, et al.
Cancer Res. 2023 Jan 4;83(1):141-157. doi: 10.1158/0008-5472.CAN-22-0391.
Cancer Res. 2023.
PMID: 36346366
Free PMC article.
Clinical Trial.
Item in Clipboard
Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer.
Stalnecker CA, Coleman MF, Bryant KL.
Stalnecker CA, et al.
Autophagy. 2022 Jul;18(7):1737-1739. doi: 10.1080/15548627.2022.2042782. Epub 2022 Feb 24.
Autophagy. 2022.
PMID: 35201948
Free PMC article.
Item in Clipboard
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Stalnecker CA, Grover KR, Edwards AC, Coleman MF, Yang R, DeLiberty JM, Papke B, Goodwin CM, Pierobon M, Petricoin EF, Gautam P, Wennerberg K, Cox AD, Der CJ, Hursting SD, Bryant KL.
Stalnecker CA, et al.
Cancer Res. 2022 Feb 15;82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443.
Cancer Res. 2022.
PMID: 34921013
Free PMC article.
Item in Clipboard
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ.
Klomp JE, et al.
Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060.
Cell Rep. 2021.
PMID: 34852220
Free PMC article.
Item in Clipboard
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin.
Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA.
Chang WH, et al.
Cancer Lett. 2021 Oct 1;517:66-77. doi: 10.1016/j.canlet.2021.05.031. Epub 2021 Jun 8.
Cancer Lett. 2021.
PMID: 34111513
Free PMC article.
Item in Clipboard
Cite
Cite